E-resources
Peer reviewed
-
Tran, Karen C; Asfar, Pierre; Cheng, Matthew; Demiselle, Julien; Singer, Joel; Lee, Terry; Sweet, David; Boyd, John; Walley, Keith; Haljan, Greg; Sharif, Omar; Geri, Guillaume; Auchabie, Johann; Quenot, Jean-Pierre; Lee, Todd C; Tsang, Jennifer; Meziani, Ferhat; Lamontagne, Francois; Dubee, Vincent; Lasocki, Sigismond; Ovakim, Daniel; Wood, Gordon; Turgeon, Alexis; Cohen, Yves; Lebas, Eddy; Goudelin, Marine; Forrest, David; Teale, Alastair; Mira, Jean-Paul; Fowler, Robert; Daneman, Nick; Adhikari, Neill K J; Gousseff, Marie; Leroy, Pierre; Plantefeve, Gaetan; Rispal, Patrick; Courtois, Roxane; Winston, Brent; Reynolds, Steve; Birks, Peter; Bienvenu, Boris; Tadie, Jean-Marc; Talarmin, Jean-Philippe; Ansart, Severine; Russell, James A; Russell, J; Tran, K; Cheng, M; Asfar, P; Demiselle, J; Singer, J; Mann, P; Jain, F; Donohoe, K; Leung, V; Lee, T; Boyd, J; Walley, K; Sweet, D; Haljan, G; Sharif, O; Ovakim, D; Wood, G; Forrest, D; Teale, A; Reynolds, S; Birk, P; Winston, B; Fowler, R; Dameman, N; Adhikari, N; Tsang, J; Lamontagne, F; Turgeon-Fournier, A; Asfar; Demiselle; Geri, D G; Auchabie, J; Quenot, J P; Meziani, F; Dubee, V; Lasocki, S; Cohen, Y; Lebas, E; Goudelin, M; Mira, J P; Gousseff, M; Leroy, P; Plantefev, G; Rispal, P; Courtois, R; Bievenue, B; Tadie, J M; Talarmin, J P; Ansart, S; Yi, Tae Won; Levin, Adeera
Clinical infectious diseases, 07/2024Journal Article
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) down-regulates angiotensin-converting enzyme 2, potentially increasing angiotensin II. We hypothesized that losartan compared to usual care decreases mortality and is safe in patients hospitalized with coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of losartan versus usual care on 28-day mortality in patients hospitalized for acute COVID-19. Methods Eligibility criteria included adults admitted for acute COVID-19. Exclusion criteria were hypotension, hyperkalemia, acute kidney injury, and use of angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors within 7 days. Participants were randomized to losartan 25–100 mg/day orally for the hospital duration or 3 months or the control arm (usual care) in 29 hospitals in Canada and France. The primary outcome was 28-day mortality. Secondary outcomes were hospital mortality, organ support, and serious adverse events (SAEs). Results The trial was stopped early because of a serious safety concern with losartan. In 341 patients, any SAE and hypotension were significantly higher in the losartan versus usual care groups (any SAE: 39.8% vs 27.2%, respectively, P = .01; hypotension: 30.4% vs 15.3%, respectively, P < .001) in both ward and intensive care patients. The 28-day mortality did not differ between losartan (6.5%) versus usual care (5.9%) (odds ratio, 1.11 95% confidence interval, .47–2.64; P = .81), nor did organ dysfunction or secondary outcomes. Conclusions Caution is needed in deciding which patients to start or continue using ARBs in patients hospitalized with pneumonia to mitigate risk of hypotension, acute kidney injury, and other side effects. ARBs should not be added to care of patients hospitalized for acute COVID-19. Clinical Trials Registration NCT04606563.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.